Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study
The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
BACKGROUND: This study evaluated the effects of exenatide, a GLP-1 receptor agonist, and sitagliptin, a DPP-4 inhibitor, on 2-h postprandial glucose (PPG), insulin and glucagon secretion, gastric emptying, and caloric intake in T2D patients. METHODS: This double-blind, randomized cross-over, multi-center study was conducted in metformin-treated T2D patients: 54% female; BMI: 33 +/- 5 kg/m(2); HbA(1c): 8.5 +/- 1.2%; 2-h PPG: 245 +/- 65 mg/dL. Patients received exenatide (5 microg BID for 1 week, then 10 microg BID for 1 week) or sitagliptin (100 mg QAM) for 2 weeks. After 2 weeks, patients crossed-over to the alternate therapy. Postprandial glycemic measures were assessed via standard meal test; caloric intake assessed by ad libitum dinner (subset of patients). Gastric emptying was assessed by acetaminophen absorption (Clinicaltrials.gov Registry Number: NCT00477581). RESULTS: After 2 weeks of therapy, 2-h PPG was lower with exenatide versus sitagliptin: 133 +/- 6 mg/dL versus 208 +/- 6 mg/dL, p < 0.0001 (evaluable, N = 61). Switching from exenatide to sitagliptin increased 2-h PPG by +73 +/- 11 mg/dL, while switching from sitagliptin to exenatide further reduced 2-h PPG by -76 +/- 10 mg/dL. Postprandial glucose parameters (AUC, C(ave), C(max)) were lower with exenatide than sitagliptin (p < 0.0001). Reduction in fasting glucose was similar with exenatide and sitagliptin (-15 +/- 4 mg/dL vs. -19 +/- 4 mg/dL, p = 0.3234). Compared to sitagliptin, exenatide improved the insulinogenic index of insulin secretion (ratio exenatide to sitagliptin: 1.50 +/- 0.26, p = 0.0239), reduced postprandial glucagon (AUC ratio exenatide to sitagliptin: 0.88 +/- 0.03, p = 0.0011), reduced postprandial triglycerides (AUC ratio exenatide to sitagliptin: 0.90 +/- 0.04, p = 0.0118), and slowed gastric emptying (acetaminophen AUC ratio exenatide to sitagliptin: 0.56 +/- 0.05, p < 0.0001). Exenatide reduced total caloric intake compared to sitagliptin (-134 +/- 97 kcal vs. +130 +/- 97 kcal, p = 0.0227, N = 25). Common adverse events with both treatments were mild to moderate in intensity and gastrointestinal in nature. CONCLUSIONS: Although this study was limited by a 2-week duration of exposure, these data demonstrate that, exenatide had: (i) a greater effect than sitagliptin to lower postprandial glucose and (ii) a more potent effect to increase insulin secretion and reduce postprandial glucagon secretion in T2D patients. In contrast to sitagliptin, exenatide slowed gastric emptying and reduced caloric intake. These key findings differentiate the therapeutic actions of the two incretin-based approaches, and may have meaningful clinical implications.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition to the glucose-lowering actions, GLP-1RA based therapies have been reported to improve both fasting and postprandial lipid profiles in patients with T2D, in particular triglyceride concentrations [104,147,153,176,177].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [176]
Citations
Cites
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Kahn, S. E. (2003) · Diabetologia · doi:10.1007/s00125-002-1009-0 · Cited by 2,166
DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559
Self-citationStandards of Medical Care in Diabetes—2008
American Diabetes Association (2008) · Diabetes Care · doi:10.2337/dc08-s012 · Cited by 1,377
Buse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346
Kendall, D. M., Riddle, M. C., Rosenstock, J., Zhuang, D., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1083 · Cited by 1,177
Disordered lipid metabolism and the pathogenesis of insulin resistance.
Savage, D. B., Petersen, K. F., & Shulman, G. I. (2007) · Physiological Reviews · doi:10.1152/physrev.00024.2006 · Cited by 1,107
Göke, R., Fehmann, H. C., Linn, T., Schmidt, H., Krause, M., Eng, J., & Göke, B. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)36565-2 · Cited by 837 · cited 2×
“2008 Informa UK - Curr Med Res Opin 2008; 24(10) Exenatilde vs.”
Background(2007) · Endocrine Practice · doi:10.4158/ep.13.s1.1 · Cited by 699
Research works printed but not linked: 2
- Gedulin B, 2007, Diabetologia, 50, S239
- 2007, Endocr Pract, 13, 3
Cited by
Items 201–300 of 384
Incretin Therapies: Effects Beyond Glycemic Control
Mudaliar, S. R. D., & Henry, R. R. (2009) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2009.05.010 · Cited by 20
Habib, H. A., Heeba, G. H., & Khalifa, M. M. A. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119624 · Cited by 19
Scholz, G. H., & Fleischmann, H. (2014) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018814556099 · Cited by 18
Schneider, R., Kraljević, M., Peterli, R., Rohm, T. V., Klasen, J. M., Cavelti‐Weder, C., & Delko, T. (2020) · Obesity Surgery · doi:10.1007/s11695-020-04750-7 · Cited by 18
“1 Mechanisms by which GLP-1 analogues may have beneficial effects after metabolic surgery: GIT [16, 17], brain [14, 18, 19], cardiovascular system [20, 21], kidneys [22], skeletal muscle [23], adipose tissue [24, 25], liver [26, 27], and endocrine pancreas [15, 28, 29].”
BackgroundMari, A., Prato, S. D., Ludvik, B. H., Miličević, Z., de la Peña, A., Shurzinske, L., Karanikas, C. A., & Pechtner, V. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12671 · Cited by 18
Girges, C., Vijiaratnam, N., Athauda, D. S., Auld, G., Gandhi, S., & Foltynie, T. (2021) · Drugs & Aging · doi:10.1007/s40266-021-00853-7 · Cited by 18
Lixisenatide as add-on therapy to basal insulin
Evans, M., Butler, E. L., & Brown, D. X. (2013) · Drug Design Development and Therapy · doi:10.2147/dddt.s45108 · Cited by 17
“It is worth mentioning that the efficacy of stand-alone exenatide twice daily in terms of prandial glucose control has also been proven; however, combination therapy with insulin has several benefits.(15) These include improved glycemic control, reduced body weight, reduced insulin dose requirement, and possible impro…”
Schwartz, S. S., Fabricatore, A. N., & Diamond, A. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-5441-0_31 · Cited by 17
Control of Postprandial Glucose Levels with Insulin in Type 2 Diabetes
Blevins, T. (2011) · Postgraduate Medicine · doi:10.3810/pgm.2011.07.2313 · Cited by 18
“a greater reduction in PPG with GLP-1 analogs than with DPP-4 inhibitors.(60,64)”
BackgroundSarmiento, B. E., Menezes, L. F. S., & Schwartz, E. F. (2019) · Molecules · doi:10.3390/molecules24101846 · Cited by 17
Giuseppe, G. D., Ciccarelli, G., CEFALO, C. M. A., Cinti, F., Moffa, S., Impronta, F., Capece, U., Pontecorvi, A., Giaccari, A., & Mezza, T. (2021) · Minerva Endocrinology · doi:10.23736/s2724-6507.21.03405-9 · Cited by 17
Preclinical and Clinical Data on Extraglycemic Effects of GLP-1 Receptor Agonists
Gallwitz, B. (2009) · The Review of Diabetic Studies · doi:10.1900/rds.2009.6.247 · Cited by 17
“They also provide β-cell protection and other extraglycemic benefits, such as weight loss and improvements in markers of cardiovascular (CV) risk [1, 4, 7, 12, 19-21].”
BackgroundCosta, R. P. (2016) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/71gw-dc16 · Cited by 17
Efficacy and Safety of GLP-1 Receptor Agonists Across the Spectrum of Type 2 Diabetes Mellitus
Leiter, L. A., & Nauck, M. A. (2017) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0043-103969 · Cited by 16
Cao, Y., Cao, X., & Liu, X.-M. (2015) · Acta Histochemica · doi:10.1016/j.acthis.2014.12.007 · Cited by 16
Nakaya, K., Kubota, N., Takamoto, I., Kubota, T., Katsuyama, H., Sato, H., Tokuyama, K., Hashimoto, S., Goto, M., Jomori, T., et al. (2013) · Metabolism · doi:10.1016/j.metabol.2013.01.010 · Cited by 16
Pharmacokinetic drug evaluation of exenatide for the treatment of type 2 diabetes
Molina‐Vega, M., Muñoz‐Garach, A., & Tinahones, F. J. (2017) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1420160 · Cited by 16
Type 2 diabetes mellitus and the cardiometabolic syndrome: impact of incretin-based therapies
Schwartz, S. S. (2010) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmsott.s11389 · Cited by 17
“These effects are presumably due to the slowing of gastric emptying seen with exenatide.(85) Titration of exenatide to a dose of 10 μg can occur after 1 month of therapy based on clinical response.”
Borah, A. K., Ahmed, S. A., & Borah, J. C. (2022) · Phytomedicine Plus · doi:10.1016/j.phyplu.2022.100225 · Cited by 15
Incretin‐based therapies: Therapeutic rationale and pharmacological promise for type 2 diabetes
Wick, A., & Newlin, K. (2009) · Journal of the American Academy of Nurse Practitioners · doi:10.1111/j.1745-7599.2009.00455.x · Cited by 13
“The blood glucose-lowering efficacy of sitagliptin does not seem to be as great as that of the GLP-1 receptor agonists (Amori, Lau & Pittas, 2007; DeFronzo et al., 2008), nor does it have their weightreducing properties (Amori et al.”
BackgroundGastaldelli, A., Nauck, M. A., & Balena, R. (2013) · Metabolism · doi:10.1016/j.metabol.2013.05.001 · Cited by 15
“[12] DeFronzo RA, Okerson T, Viswanathan P, et al.”
BackgroundGlucagon-Like Peptide-1 and its Cardiovascular Effects
Heo, K., Fujiwara, K., & Abe, J. (2012) · Current Atherosclerosis Reports · doi:10.1007/s11883-012-0265-9 · Cited by 16
Shomali, M. E. (2014) · Clinical Diabetes · doi:10.2337/diaclin.32.1.32 · Cited by 15
The Role of Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes in Asia
Lu, J. (2019) · Advances in Therapy · doi:10.1007/s12325-019-00914-9 · Cited by 15
Lu, C., Wu, T.-J., Shih, K., Ni, E., Reed, V. A., Yu, M. B., Sheu, W. H., & Chuang, L. (2012) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2012.02.027 · Cited by 15
Exploring the multifaceted roles of GLP-1 receptor agonists; a comprehensive review
Hammad, B. F., Zafar, N., Ullah, M., Faisal, S. J., Iftikhar, F., Waheed, H., Muzaffar, M. W., Ahmed, K., Ashraf, F., Zahid, K., et al. (2025) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2025.1590530 · Cited by 14
Hølmkjær, K. M., Albrechtsen, N. J. W., Holst, J. J., Cronin, A. M., Nielsen, D. H., Mandrup-Poulsen, T. R., & Bjørnvad, C. R. (2016) · PLoS ONE · doi:10.1371/journal.pone.0154727 · Cited by 14
“Nausea and vomiting are the most common adverse reactions, especially during the initial weeks, and a stepwise dose escalation is recommended[6, 7].”
BackgroundResultHissa, M. R. N., Cavalcante, L. L. A., Guimarães, S. B., & Hissa, M. N. (2015) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-015-0058-8 · Cited by 14
“Clinical studies in T2DM with DPP-4 inhibitors provide evidences that incretinbased therapies improve fasting and postprandial glycemia and somewhat also dyslipidemia [22–25].”
Incorporating Incretin-Based Therapies into Clinical Practice for Patients with Type 2 Diabetes
Tibaldi, J. M. (2014) · Advances in Therapy · doi:10.1007/s12325-014-0100-5 · Cited by 14
Lage, M. J., Fabunmi, R. P., Boye, K. S., & Misurski, D. A. (2009) · Advances in Therapy · doi:10.1007/s12325-009-0002-0 · Cited by 14
Ethnic Differences in Efficacy and Safety of Alogliptin: A Systematic Review and Meta-Analysis
Cai, Y., Zeng, T., Wen, Z., & Chen, L. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0352-6 · Cited by 14
Cao, Y., & Liu, X.-M. (2014) · Endocrine · doi:10.1007/s12020-014-0354-3 · Cited by 14
Paul, S., Best, J., Klein, K., Han, J., & Maggs, D. (2012) · Diabetes, obesity and metabolism · doi:10.1111/j.1463-1326.2012.01609.x · Cited by 15
Incretin-Related Therapies in Type 2 Diabetes: A Practical Overview
Robertson, C. (2011) · Diabetes Spectrum · doi:10.2337/diaspect.24.1.26 · Cited by 14
Nonaka, T., Sekino, Y., Iida, H., Yamada, E., Ohkubo, H., Sakai, E., Higurashi, T., Hosono, K., Endo, H., Koide, T., et al. (2013) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm.2013.19.2.227 · Cited by 13
“inhibitor-induced enhancement of endogenous incretin hormones on gastrointestinal motility has not yet been sufficiently investigated.(11,12) In the present study, the pharmacological effects”
BackgroundClinical utility of fixed combinations of sitagliptin–metformin in treatment of type 2 diabetes
Green, J., Karen, K., & Cox, M. E. (2010) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmsott.s10195 · Cited by 13
“5%), DeFronzo et al compared sitagliptin–metformin with exenatide–metformin.(34) Subjects who were on a stable dose of metformin were randomized to either exenatide or sitagliptin for two weeks and crossed over to the alternative therapy for another two weeks.”
Wang, C., Li, S., Meng, Q., Sun, X., Li, H., Shu, X. H., Sun, H., Liu, K., Liu, Z., & Ma, X. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.07.007 · Cited by 13
Incretin-based Therapy in Chronic Kidney Disease
Pinelli, N. R., Moore, C. L., & Tomasello, S. (2010) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2010.06.003 · Cited by 13
Practical implementation of incretin-based therapy in hospitalized patients with type 2 diabetes
Schwartz, S. S., DeFronzo, R. A., & Umpierrez, G. E. (2014) · Postgraduate Medicine · doi:10.1080/00325481.2015.996504 · Cited by 12
“Because DPP-4 inhibitors are less potent than the GLP-1 receptor agonists in promoting insulin and inhibiting glucagon secretion [27,51], it is likely that they will be less efficacious in controlling hyperglycemia in these more critically ill patients.”
BackgroundResultSelf-citationGentilella, R., Romera, I., Nicolay, C., Buzzetti, R., Vázquez, L. A., & Sesti, G. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0625-3 · Cited by 12
Shin, J., Chang, J., Kim, H., Ko, S.-H., Cha, B., Son, H., Yoon, K., & Cho, J. (2012) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2012.36.5.364 · Cited by 12
“GLP-1 is a gut hormone that not only lowers glucose levels by promoting insulin secretion and inhibiting glucagon release, but also controls weight by inducing satiety and slowing gastric emptying time [10,11].”
Background3D-QSAR and docking studies of arylmethylamine-based DPP IV inhibitors
Jiang, C., Han, S., Chen, T., & Chen, J. (2012) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2012.06.007 · Cited by 12
Quddos, F., Fowler, M., Bovo, A. C. D. L., Elbash, Z., Tegge, A. N., Gatchalian, K. M., Kablinger, A. S., DiFeliceantonio, A. G., & Bickel, W. K. (2025) · Scientific Reports · doi:10.1038/s41598-025-17927-w · Cited by 11
Rationale for treatment options for mealtime glucose control in patients with type 2 diabetes
Aronoff, S. L. (2017) · Postgraduate Medicine · doi:10.1080/00325481.2017.1285191 · Cited by 11
Peterson, G. M. (2012) · Annals of Medicine · doi:10.3109/07853890.2011.653392 · Cited by 11
Cardiovascular Effects of Incretin Therapy in Diabetes Care
Kim, J., & Samson, S. L. (2014) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2014.0035 · Cited by 11
“Reduction of postprandial hypertriglyceridemia was not necessarily associated with delayed gastric emptying.(36,37) Notably, the effect of the DPP-4 inhibitor sitagliptin was smaller than that of exenatide.”
BackgroundResultExenatide, a GLP-1 agonist in the treatment of Type 2 diabetes
Sennik, D., Ahmed, F. W., & Russell-Jones, D. (2012) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.11.79 · Cited by 10
Newly appreciated therapeutic effect of GLP-1 receptor agonists: Reduction in postprandial lipemia
Bandsma, R., & Lewis, G. F. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.06.033 · Cited by 11
“In two separate studies, 2 weeks of exenatide treatment in patients with T2DM resulted in significantly decreased postprandial triglyceride concentrations [7,8].”
BackgroundTrautmann, M. E., Han, J., & Ruggles, J. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.03.039 · Cited by 11
“Because these agents act by supplementing endogenous GLP-1 activity, treatment with high concentrations of GLP-1RAs can produce stronger effects compared with dipeptidyl peptidase-4 inhibitors, which act by inhibiting proteolytic cleavage of endogenous GLP-1 and produce only 2- to 3-fold increases in plasma GLP-1 conc…”
BackgroundHaluzík, M., Mráz, M., & Svacina, S. (2014) · Drug Safety · doi:10.1007/s40264-014-0238-8 · Cited by 10
“The treatment with DPP-4 inhibitors thus prolongs the halflife of endogenous GLP-1 increasing its concentrations to the high-normal physiological range [12].”
BackgroundIs It Time for a New Algorithm for the Pharmacotherapy of Steroid-Induced Diabetes?
Ostrowska-Czyżewska, A., Zgliczyński, W., Papierska, L., & Mrozikiewicz‐Rakowska, B. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13195801 · Cited by 10
Gastaldelli, A., Balas, B., Ratner, R. E., Rosenstock, J., Charbonnel, B. H., Bolli, G. B., Boldrin, M. N., & Balena, R. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12192 · Cited by 10
“Exenatide twice-daily has been shown to efficiently reduce postprandial glucose excursions following ingestion of a mixed meal, and to improve fasting blood glucose as well [11,19].”
BackgroundInfluentialGrunberger, G. (2014) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-014-1727-5 · Cited by 10
The effect of DPP-4-protected GLP-1 (7–36) on coronary microvascular function in obese adults
Nilsson, M. S. D., Bove, K. B., Suhrs, H. E., Hermann, T. S., Madsbad, S., Holst, J. J., Prescott, E., & Zander, M. (2019) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2019.01.004 · Cited by 10
Tamura, Y., Kimbara, Y., Funatsuki, S., Mabuchi, S., Kodera, R., Yoshimoto, A., Chiba, Y., Mori, S., Ito, H., & Araki, A. (2012) · Diabetology International · doi:10.1007/s13340-012-0100-0 · Cited by 10
“Although DPP-4 inhibitors also increase serum GLP-1 levels, there is a strong evidence that GLP-1 analogues have stronger effect over DPP-4 inhibitor in normalizing postprandial hyperglycemia [16].”
BackgroundClinical overview of saxagliptin for Type 2 diabetes management
Rosenstock, J. (2010) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.10.60 · Cited by 10
Krishnan, A., Suryanarayanan, S., & Mansi, I. A. (2024) · Journal of Pharmacy Technology · doi:10.1177/87551225241266773 · Cited by 9
Evidence-Based Practice Use of Incretin-Based Therapy in the Natural History of Diabetes
Schwartz, S. S. (2014) · Postgraduate Medicine · doi:10.3810/pgm.2014.05.2757 · Cited by 9
Key considerations in pharmacotherapy for type 2 diabetes mellitus: a multiple target organ approach
Cornell, S. A. (2011) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2011.01302.x · Cited by 9
“the human GLP1 analogue, liraglutide, and the incretin mimetic, exenatide) produce high levels of the GLP-1 receptor agonist in the circulation and pharmacological levels of GLP-1 receptor stimulation.(20) Exogenous GLP-1 receptor agonists such as liraglutide show biological activity similar to native GLP-1 and are re…”
BackgroundSchwartz, S. S., & DeFronzo, R. A. (2014) · Current Diabetes Reports · doi:10.1007/s11892-013-0466-9 · Cited by 9
Self-citationAlanazi, A. (2014) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2013.12.018 · Cited by 9
“However, DeFronzo et al. (2008)have noted an inverse relationship between increasing doses of SAXA-MET and mean changes from baseline in body weight ( (cid:2) 1.43, (cid:2) 0.87, and (cid:2) 0.53 kg for 2.5, 5, and 10 mg) at week 24 of treatment.”
InfluentialManaging Type 2 Diabetes in the Primary Care Setting: Beyond Glucocentricity
Kuritzky, L. (2010) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e3181d64344 · Cited by 9
Neto, S. R. M., Castiglione, R. C., Pontes, A., de Oliveira, D. F., Ferraz, E. B., Nascimento, J. H. M., & Bouskela, E. (2016) · PLoS ONE · doi:10.1371/journal.pone.0148402 · Cited by 9
Recent Advances in Clinical Application of Gut Hormones
Tseng, P., Wu, M., & Kao, J. (2010) · Journal of the Formosan Medical Association · doi:10.1016/s0929-6646(10)60132-5 · Cited by 8
Zhang, Y., Chi, J., Wang, W., Hong, J., Gu, W., Wang, B., & Ning, G. (2014) · Journal of Diabetes · doi:10.1111/1753-0407.12175 · Cited by 8
“demonstrated a dose-dependent inhibition of plasma DPP-4 activity by sitagliptin that increased insulin/C-peptide but decreased glucagon secretion during an oral glucose tolerance test (OGTT) in drugnaïve T2D patients; DeFronzo et al.(13) also reported similar results for sitagliptin on insulin and glucagon secretion…”
BackgroundResultPrajapat, R., & Bhattacharya, I. (2016) · Advances in Diabetes and Metabolism · doi:10.13189/adm.2016.040403 · Cited by 8
“However, there is still a need for more potent, selective and safer DPP4 inhibitor, which does not have the inspecificity and side effect possessed by the presently available inhibitors [13], because of worldwide problem of type 2 diabetes.”
BackgroundBennett, D., Davé, S., Sakaguchi, M., Chang, C., & Dolin, P. (2016) · Diabetology International · doi:10.1007/s13340-016-0261-3 · Cited by 8
Nodular panniculitis in a female toy poodle.
Post, K. (1983) · PubMed · Cited by 8
Glucagon-Like Peptide-1 and Diabetes
Monami, M. (2011) · Experimental Diabetes Research · doi:10.1155/2011/901954 · Cited by 8
“[82] B.”
BackgroundCurrent Issues in Glp-1 Receptor Agonist Therapy for Type 2 Diabetes
Bloomgarden, Z. T., Blonde, L., Garber, A. J., & Wysham, C. (2012) · Endocrine Practice · doi:10.4158/ep12300.ra · Cited by 8
Historical overview of incretin based therapies
Bhansali, A., Maji, D., Rao, P. V. C., Banerjee, S., & Kumar, H. D. (2010) · Journal of the Association of Physicians of India · Cited by 7
Shaefer, C. F. (2016) · Clinical Diabetes · doi:10.2337/diaclin.34.2.81 · Cited by 7
“Studies also show that liraglutide, as well as DPP-4 inhibitors such as sitagliptin, do not demonstrate long-term deceleration of gastric emptying (9,32).”
BackgroundInfluentialCardiovascular Safety of Antidiabetic Drugs in the Hospital Setting
Seggelke, S. A., Lindsay, M. C., Hazlett, I., Sanagorski, R., Eckel, R. H., & Wang, C. C. L. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0884-1 · Cited by 7
Liu, X., Liu, Y., Liu, H., Li, H., Yang, J., Hu, P., Xiao, X., & Liu, D. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.694390 · Cited by 8
“However, some studies have shown that GLP-1 delays gastric emptying, whereas DPP-4 inhibitors do not (38, 39), which may cause the resulting rise in peripheral active GLP1 concentrations to be not sustained, in marked contrast to concentrations observed during peripheral GLP-1 infusion.”
ResultClinical efficacy of GLP-1 agonists and their place in the diabetes treatment algorithm.
Unger, J. (2011) · PubMed · Cited by 9
Controlling Release by Gastroretention
Coffin, M. D., & Burke, M. D. (2011) · Springer eBooks · doi:10.1007/978-1-4614-1004-1_17 · Cited by 7
Nakagawa, T., Nagai, Y., Yamamoto, Y. L., Miyachi, A., Hamajima, H., Mieno, E., Takahashi, M., Inoue, E., & Tanaka, Y. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.107892 · Cited by 8
Yamada, Y., Senda, M., Naito, Y., Tamura, M., Watanabe, D., Shuto, Y., & Urita, Y. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12945 · Cited by 6
“tying rate, suppressed appetite, and weight loss, which are not seen routinely with DPP-4 inhibitor treatments.(22,23) Lixisenatide is a short-acting GLP-1 receptor agonist confirmed to improve glycaemic control when taken once daily in patients with T2D as monotherapy(24) and in those insufficiently controlled on a r…”
BackgroundBouzas, C., Pastor, R., García, S., Monserrat-Mesquida, M., Martínez‐González, M. Á., Salas‐Salvadó, J., Corella, D., Goday, A., Martínez, J. A., Alonso‐Gómez, Á. M., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114561 · Cited by 6
“Lately there have been published reviews that have focused on the effect of GLP-1RA and DPP-4I on MetS [17,18].”
A patient-centred approach to treatment with incretin-based agents in patients with type 2 diabetes
Cornell, S. A. (2013) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12040 · Cited by 6
“Exenatide greatly reduces postprandial glucose (PPG) and glucagon secretion and increases insulin secretion compared with sitagliptin.(13,14) Exenatide-ER provides better and more sustained glucose control and weight loss, with minimal hypoglycaemia and better treatment satisfaction than sitagliptin.”
BackgroundTargeting the Incretin System in Type 2 Diabetes Mellitus
Potenza, M. V., & Rayfield, E. J. (2009) · Mount Sinai Journal of Medicine A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20112 · Cited by 6
Linagliptin for the treatment of Type 2 diabetes
Tella, S. H., Aktürk, H. K., & Rendell, M. (2013) · Diabetes Management · doi:10.2217/dmt.13.55 · Cited by 6
Effects of Sitagliptin on Insulin and Glucagon Levels in Type 2 Diabetes Mellitus
Kim, J. H. (2015) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2015.39.4.304 · Cited by 6
“In shortterm clinical study of 2 weeks, sitagliptin reduced mean postprandial plasma glucagon concentration relative to baseline [6].”
BackgroundHanna, A., Connelly, K. A., Josse, R. G., & McIntyre, R. S. (2014) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2015.972370 · Cited by 6
“Types of incretin therapy and their actions [5,87–89].”
BackgroundNew therapeutic options: management strategies to optimize glycemic control.
Freeman, J. S. (2010) · PubMed · Cited by 6
Sitagliptin: A DPP-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus
Johnson, K., & Schurr, K. (2011) · Clinical Medicine Insights Therapeutics · doi:10.4137/cmt.s6227 · Cited by 5
Watkins, J. D., Smith, H., Hengist, A., Brunsgaard, L. H., Mikkelsen, U. R., Koumanov, F., Betts, J. A., & Gonzalez, J. T. (2021) · British Journal Of Nutrition · doi:10.1017/s000711452100297x · Cited by 5
“at increasing/preserving GLP-1 action and promoting weight loss and greater glycaemic control (5; 6; 7; 8) .”
BackgroundThe clinical application of linagliptin in Asians
Zhou, Z., Cao, C., & Xiang, Y. (2015) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s64402 · Cited by 5
“DPP-4 inhibitor class could effectively improve glucose homeostasis and is particularly effective in reducing PPG excursions in a glucose-dependent manner.(48) As a xanthine-based DPP-4 inhibitor, linagliptin was proposed to have an antioxidative stress action in vitro at least partly via its inhibition of xanthine ox…”
Deng, W., Qiu, S., Yang, G., & Chen, B. (2015) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s81088 · Cited by 6
“However, head-to-head trials have demonstrated that DPP-4 inhibitors have an inferior glucose-lowering effect when compared with GLP-1.(43,44) Moreover, DPP-4 inhibitors do not appear to have an effect on gastric emptying or weight loss, which limits their clinical application.”
InfluentialRepas, T. B. (2014) · Journal of Osteopathic Medicine · doi:10.7556/jaoa.2014.085 · Cited by 5
Unger, J., & Parkin, C. G. (2009) · Insulin · doi:10.1016/s1557-0843(09)80029-8 · Cited by 5
Tierney, K. (2012) · Journal of the American Academy of Nurse Practitioners · doi:10.1111/j.1745-7599.2012.00720.x · Cited by 6
Pancreatic β Cells in Metabolic Syndrome
Hiriart, M., Velasco, M., Díaz‐García, C. M., Larqué, C., Sánchez-Soto, C., Albarado-Ibáñez, A., Chávez‐Maldonado, J. P., Toledo, A., & García-Delgado, N. (2014) · Springer eBooks · doi:10.1007/978-94-007-6686-0_27 · Cited by 4
Unger, J., Hinnen, D., Schreiner, B., & Parkin, C. (2013) · Journal of the American Academy of Nurse Practitioners · doi:10.1111/j.1745-7599.2012.00736.x · Cited by 4
“Although both GLP-1 receptor agonists and DPP-4 inhibitors improve glycemic control, there are important pharmacologic differences between the two drug classes (DeFronzo et al., 2008).”
BackgroundTreating Type 2 Diabetes Mellitus
Herzlinger, S., & Abrahamson, M. J. (2009) · Springer eBooks · doi:10.1007/978-0-387-09841-8_44 · Cited by 4
Intensifying Treatment Beyond Monotherapy in Type 2 Diabetes Mellitus: Where Do Newer Therapies Fit?
Kühn, A., Park, J., Ghazi, A., & Aroda, V. R. (2017) · Current Cardiology Reports · doi:10.1007/s11886-017-0832-3 · Cited by 4
Hamidi, V., Riggs, K. A., Zhu, L., Andre, K. B. S., Westby, C. M., Coverdale, S., Le, A., Wang, H., Miller, C., III, Taegtmeyer, H., et al. (2020) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2019.0102 · Cited by 4
“Other studies suggest this effect with exenatide at 2 hr after high-fat meal and resolution after 4 hr; the effect is not seen in DPP-IV inhibitors.(23,38) Some changes in fat-induced vasodilation may be explained by gastric emptying.”
BackgroundYan, T., Nian, T., Li, F., He, B., Jia, Y., Bi, K., & Wang, Z. (2020) · Journal of Food Biochemistry · doi:10.1111/jfbc.13446 · Cited by 4
RetractedIn silico Molecular Docking Studies of Some Phytochemicals against Dipeptidyl peptidase 4
Ahmed, H. A., Y, A. I., & Mahmud, A. F. (2018) · Zenodo (CERN European Organization for Nuclear Research) · doi:10.5281/zenodo.2538629 · Cited by 4
Tsai, C.-J., & Tsao, C. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12111915 · Cited by 4
“DeFronzo and colleagues found that subjects who were administered exenatide had a significant reduction in 2-h postprandial glucose [14].”
Background
Metadata
- Authors
- DeFronzo, R. A., Okerson, T., Viswanathan, P., Guan, X., Holcombe, J. H., & MacConell, L.
- Affiliations
- The University of Texas at San Antonio Health Science Center (US)
- Amylin Pharmaceuticals, Inc., San Diego, CA, USA
- Eli Lilly (United States) (US)
- Corresponding author
- DeFronzo, Ralph A.
- ORCID
- DeFronzo, Ralph A.
- Venue
- Current Medical Research and Opinion
- Publisher
- Informa UK Limited
- Published
- 2008-09-10
- Volume
- 24
- Issue
- 10
- Pages
- 2943-2952
- ISSN
- 0300-7995 (ISSN-L)
- 1473-4877
- OpenAlex
- W2159198773
- Cited by
- 373
- References
- 33
- Citations by year
- 2026: 3 · 2025: 6 · 2024: 8 · 2023: 3 · 2022: 6 · 2021: 11 · 2020: 14 · 2019: 7 · 2018: 12 · 2017: 19 · 2016: 20 · 2015: 23 · 2014: 38 · 2013: 36 · 2012: 40
- FWCI
- 30.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Medical Research and Opinion (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- exenatide, sitagliptin, type 2 diabetes, postprandial blood glucose, insulin secretion, glucagon secretion, gastric emptying, energy intake, GLP-1 receptor agonists, DPP-4 inhibitors, insulinogenic index, metformin, glycemic control, drug comparison, fasting blood glucose
- MeSH terms
- Sitagliptin Phosphate, Exenatide, Insulin Secretion, Blood Glucose, Energy Intake, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Glucagon, Humans, Hypoglycemic Agents, Insulin, Male, Middle Aged, Peptides, Pyrazines, Stomach, Triazoles, Venoms, Cross-Over Studies, Postprandial Period
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.